Cost savings of home bortezomib injection in patients with multiple myeloma treated by a combination care in Outpatient Hospital and Hospital care at Home

Bortezomib cumulative dose, efficacy, and tolerability with three different bortezomib-melphalan-prednisone regimens in previously untreated myeloma patients ineligible for high-dose therapy

(2014) M.-V. Mateos et al.   HAEMATOLOGICA

Patient perceptions of a mobile cancer support unit in South Wales

(2011) R. IREDALE et al.   EUROPEAN JOURNAL OF CANCER CARE

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Home care—a safe and attractive alternative to inpatient administration of intensive chemotherapies

(2011) François Lüthi et al.   SUPPORTIVE CARE IN CANCER

Comparison between ambulatory infusion mode and inpatient infusion mode from the perspective of quality of life among colorectal cancer patients receiving chemotherapy

(2010) Yik M Lee et al.   International Journal of Nursing Practice

Economic and patient-reported outcomes of outpatient home-based versus inpatient hospital-based chemotherapy for patients with colorectal cancer

(2010) Eun-Hye Joo et al.   SUPPORTIVE CARE IN CANCER

Home administration of bortezomib: Making a difference to myeloma patients' lives

(2009) Teresa Meenaghan et al.   European Journal of Oncology Nursing

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression

(2008) M.-V. Mateos et al.   HAEMATOLOGICA

Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma

(2008) Jesús F. San Miguel et al.   NEW ENGLAND JOURNAL OF MEDICINE